Patient preferences for ITP treatment
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living in the United States.
- You must be 18 years or older.
- You must have been diagnosed with primary immune thrombocytopenia (ITP).
- If you are in first-line treatment, you must have started corticosteroids within 3 months of diagnosis and responded to them.
- If you are in second-line treatment, you must need or be taking a TPO-RA and have previously had an insufficient response to corticosteroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.